Major updates to ADHD medication rules in New Zealand take effect from February 1, 2026, easing access for adults seeking diagnosis and treatment. These changes aim to address long waitlists and specialist shortages by empowering general practitioners and nurse practitioners.
Background on ADHD in New Zealand
Attention Deficit Hyperactivity Disorder affects around five percent of children and two point six percent of adults in New Zealand, yet many remain undiagnosed or untreated. Common symptoms include inattention, hyperactivity, and impulsivity that disrupt daily life, work, education, and relationships. In children aged two to fourteen, diagnosis rates have climbed, with males at seven point nine percent and females at two point six percent by mid-2024, reflecting growing awareness.
Historically, stimulant medications like methylphenidate, dexamfetamine, and lisdexamfetamine offered relief, but strict rules limited access. Prescriptions required initiation by paediatricians or psychiatrists, followed by a written recommendation for general practitioners to continue. This created bottlenecks, with wait times stretching years and costs burdening patients. Adult treatment rates lagged at just zero point six percent in 2022, highlighting a vast gap.
Key Changes Effective February 2026
From February first, general practitioners and nurse practitioners gain authority to diagnose ADHD and initiate stimulant prescriptions for adults aged eighteen and older, without specialist involvement. Nurse practitioners in mental health services extend this to those under eighteen. This shift, announced by Pharmac and Medsafe in June 2025, removes prescriber restrictions on funded stimulants.
Special Authority criteria simplify: any relevant practitioner can now apply, ditching requirements for specialist applications or recommendations. Medications become interchangeable where clinically suitable—methylphenidate, lisdexamfetamine, and dexamfetamine—for supply issues, provided no restrictions apply. Immediate-release methylphenidate shifts to generic prescribing to aid flexibility during shortages.
These rules respond to advocacy from clinicians, patients, and Mental Health Minister Matt Doocey, prioritizing faster care amid rising demand.
Who Can Prescribe and Under What Conditions
| Prescriber Type | Age Group Allowed | Requirements for Initiation | Continuation Prescribing |
|---|---|---|---|
| General Practitioners | 18+ | Diagnosis + Special Authority; training recommended | Yes, with handover plan |
| Nurse Practitioners (General) | 18+ | Same as GPs | Yes |
| Nurse Practitioners (Mental Health) | 17 and under | Diagnosis + Special Authority | Yes |
| Paediatricians/Psychiatrists | All ages | No change; prior rules | Unchanged |
This table outlines expanded roles, emphasizing vocational training for safe practice.
GPs and nurse practitioners must follow clinical guidelines, including comprehensive assessments using standardized tools like the DSM-5 criteria. While no mandatory national training exists yet, resources from bpac and the Royal New Zealand College of General Practitioners prepare prescribers. Vocationally trained GPs lead, akin to specialists in dermatology or travel medicine.
Impact on Patients: Easier Access and What to Expect
Patients stand to gain quicker pathways to care, bypassing specialist queues often exceeding twelve months. Adults suspecting ADHD can now approach their GP for evaluation, potentially securing funded medication sooner. First-line options include methylphenidate formulations like Concerta or Ritalin LA, alongside lisdexamfetamine and dexamfetamine, tailored to symptoms.
Expect a thorough process: history review, symptom checklists, collateral input from family, and ruling out mimics like anxiety or sleep issues. Successful applicants receive Special Authority approval for subsidized supply. During shortages, pharmacists may dispense alternate strengths or immediates without new scripts, easing disruptions.
Challenges persist—global supply crunches for long-acting methylphenidate continue into 2026, prompting Pharmac to fund extras like Methylphenidate Sandoz XR from December 2025. Patients should monitor stocks via Healthify and discuss non-stimulant alternatives if needed.
Guidance for Doctors: Best Practices and Training
Doctors must prioritize evidence-based diagnosis, documenting functional impairment across settings. Start low doses—methylphenidate at ten milligrams immediate-release—and titrate based on response, monitoring heart rate, blood pressure, and side effects like appetite loss or insomnia. Annual reviews ensure ongoing need.
Training modules from bpac cover psychostimulants’ pharmacokinetics, varying by formulation. Modified-release brands like Concerta require specific prescribing; generics suit immediates. Interchangeability aids supply but demands clinical judgment.
Prescribers apply for Special Authority online, detailing diagnosis and plan. Handover notes from specialists facilitate continuations. Collaborate with mental health services for complex cases, upholding equity for Māori and Pasifika via cultural safety.
Common ADHD Medications and Formulations
Stimulants dominate treatment, with diverse options for dosing flexibility.
| Medication | Common Brands | Formulation Types | Typical Adult Dose Range | Key Notes |
|---|---|---|---|---|
| Methylphenidate | Ritalin, Concerta, Teva ER | Immediate, Long-acting (LA/XR) | 10-60mg daily | Most funded; supply variable |
| Lisdexamfetamine | Vyvanse (funded option) | Long-acting prodrug | 30-70mg daily | Smoother profile; less abuse potential |
| Dexamfetamine | Dexies | Immediate-release | 5-40mg daily | For non-responders; controlled |
This table aids selection, noting funded status via Special Authority.
Pharmac ensures broad access, funding first-line choices with criteria met.
Addressing Supply Challenges and Safety
Ongoing global disruptions since 2023 affect long-acting methylphenidate, driven by demand surges and manufacturing limits. Pharmac mitigates via new brands, minimum stocks, and flexible dispensing—alternate strengths okay if total dose matches.
Safety emphasizes cardiovascular screening pre-start, avoiding in uncontrolled hypertension or psychosis history. Report adverse events to Medsafe. Non-drug supports—therapy, coaching—complement meds for holistic management.
Broader Implications and Future Outlook
These updates could tenfold prescriptions, mirroring past trends, narrowing the treatment gap. Equity demands training rollout and rural access. Critics worry untrained prescribing risks overdiagnosis; advocates hail relief for underserved adults.
Monitoring via Pharmac ensures supply stability. Complementary reforms—like neurodiversity briefings—bolster support. Patients and doctors alike benefit from empowered primary care, transforming ADHD management in Aotearoa.
Nirti Singh is a news writer and digital content contributor at KorakoSpecklePark, covering key stories and regional developments across New Zealand and Australia. Her work focuses on clear, fact-based reporting, ensuring readers receive accurate and timely information.